ReviewJournal of gastroenterology2019
Antimicrobial proteins: intestinal guards to protect against liver disease.
Review in Journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Liver as a key organ for systemic antimicrobial defense.Hepatology communications · 2025Review
- Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.Hepatology (Baltimore, Md.) · 2024Review
- Macrophages and the development and progression of non-alcoholic fatty liver disease.Frontiers in immunology · 2023Review
- 35kDa hyaluronan ameliorates ethanol driven loss of anti-microbial defense and intestinal barrier integrity in a TLR4-dependent manner.Matrix biology : journal of the International Society for Matrix Biology · 2023Article
- Indolepropionic Acid, a Gut Bacteria-Produced Tryptophan Metabolite and the Risk of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease.Nutrients · 2022Review
- Multi-Omics Analysis Reveals the Protection of Gasdermin D in Concanavalin A-Induced Autoimmune Hepatitis.Microbiology spectrum · 2022Article
- An Overview of the Potentialities of Antimicrobial Peptides Derived from Natural Sources.Antibiotics (Basel, Switzerland) · 2022Review
- Role of Intestinal Microbes in Chronic Liver Diseases.International journal of molecular sciences · 2022Review
- Resistance is futile? Mucosal immune mechanisms in the context of microbial ecology and evolution.Mucosal immunology · 2022Review
- Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.International journal of biological sciences · 2022Review
- The Gut Microbiota-Derived Immune Response in Chronic Liver Disease.International journal of molecular sciences · 2021Review
- Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD.Tissue barriers · 2021Review
- Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.International journal of molecular sciences · 2021Review
- Hepatoprotective effect of Saccharomyces Cervisciae Cell Wall Extract against thioacetamide-induced liver fibrosis in rats.Heliyon · 2021Article
- Blood Biomarkers of Intestinal Epithelium Damage Regenerating Islet-derived Protein 3α and Trefoil Factor 3 Are Persistently Elevated in Patients with Alcoholic Hepatitis.Alcoholism, clinical and experimental research · 2021Article
- Human Beta Defensin 2 Ameliorated Alcohol-Associated Liver Disease in Mice.Frontiers in physiology · 2021Article
- Gut microbiome, liver immunology, and liver diseases.Cellular & molecular immunology · 2021Review
- A Perspective Of Intestinal Immune-Microbiome Interactions In Alcohol-Associated Liver Disease.International journal of biological sciences · 2021Review
- Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alterations of gut microbes play a role in the pathogenesis and progression of many disorders including liver and gastrointestinal diseases. Both qualitative and quantitative changes in gut microbiota have been associated with liver disease. Intestinal dysbiosis can disrupt the integrity of the intestinal barrier leading to pathological bacterial translocation and the initiation of an inflammatory response in the liver. In order to sustain symbiosis and protect from pathological bacterial translocation, antimicrobial proteins (AMPs) such as a-defensins and C-type lectins are expressed in the gastrointestinal tract. In this review, we provide an overview of the role of AMPs in different chronic liver disease such as alcoholic steatohepatitis, non-alcoholic fatty liver disease, and cirrhosis. In addition, potential approaches to modulate the function of AMPs and prevent bacterial translocation are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.